CORPORATE INVESTORS PRODUCTS BUSINESS DEVELOPMENT CAREERS CONTACT US HOME

Menu

Financial Statements
  • Financial Reports
  • Securities Filing
      
    Investor Resources
  • Fact Sheet
  • Presentations
  • Analyst Coverage
  • Calendar of Events
  • FAQ
  • Shareholder
         Services

  • Investor Kit
  • Investor Information

    News
  • Press Releases
  • Corporate News
  • Awards
  •   FAQ: QUESTIONS AND ANSWERS


    1. Can you provide a brief description of the company?
    Paladin Labs, headquartered in Montreal, Quebec, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's most profitable publicly-traded pharmaceutical companies.

    2. What is Paladin’s ticker symbol?
    Paladin is listed on the Toronto Stock Exchange (TSX) under the symbol “PLB”.

    3. How do I purchase Paladin shares?
    To buy shares of Paladin, contact a brokerage firm or an online brokerage house. Paladin does not have a direct stock purchase plan. 
                                                                                         
    4. Does Paladin issue dividends?
    Currently, Paladin does not issue dividends.

    5. Who should I contact regarding my stock certificate?
    All questions regarding your ownership of Paladin shares should be addressed to the Company’s transfer agent, Computershare.

      Computershare Investor Services Inc.
      1500 University Street
      Suite 700
      Montreal, Québec
      Canada, H3A 3S8

      Phone: 1-800-564-6253 / 514-982-7555
      Fax: 1-888-453-0330 / 416-263-9394
      Email: service@computershare.com

    6. When is the next Annual Shareholder Meeting?
    The next AGM Meeting will be held Tuesday May 8, 2007.

    7. How many shares are outstanding?
    There are currently 14,902,784 shares issued and outstanding.

    8. When is Paladin’s fiscal year?
    Paladin has a January 1 to December 31 fiscal year.
                                                                                         

    9. How do I obtain a copy of the Annual Report?
    Paladin’s annual reports are available online. You can download an Acrobat Reader version of the 2007, 2006, 2005, 2004, 2003, 2002, 2001, 2000, 1999, 1998, and 1997 annual reports. If you still require a hard copy version, contact Paladin Investor Relations at info@paladin-labs.com.

    10. I am a potential investor. How do I obtain a Paladin investor kit?
    You can request information on Paladin’s website, under Investor Relations. You can also contact Paladin’s Investor Relations at info@paladin-labs.com.

    11. How do I contact Paladin Investor Relations?
    You can contact Paladin’s Investor Relations through any of the following:

      Email: info@paladin-labs.com 
      Phone: (514) 340-5067
      Fax: (514) 344-4675
      Mail: 6111 Royalmount Ave.
      Suite 102
      Montreal,Quebec
      Canada
      H4P 2T4
      ATTENTION: SAMIRA SAKHIA (514) 340-1112 x 3042


    12. Have you had any stock splits?
    Paladin has not had a stock split of its shares.

    13. When will Paladin’s annual report be available?
    June 2008.

    14. Who are your auditors?
    Paladin’s financial statements are audited by Ernst & Young LLP.
                                                                                         

    15. Where are the Paladin offices located?

    Paladin’s offices are located at
      6111 Royalmount Ave
      Suite 102
      Montreal, QC
      Canada H4P 2T4
      Tel.: (514) 340-1112

    16. What is Paladin’s official accounting currency?
    As a Canadian company, Paladin’s financial statements are reported in Canadian dollars.

    17. Can you provide information on the company’s major business areas?
    Please go to link to pipeline.

    18. Can you provide a list of the company’s principal products?
    Please go to link to products page.

     

    Join the broadcast

       Q3, 2008 &
    conference call


    HOME | SITE MAP | LEGAL DISCLAIMER